Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	08/444,791-Conf. #5613
Filing Date	May 19, 1995
First Named Inventor	Manfred Brockhaus
Art Unit	1644
Examiner Name	R. B. Schwadron
Attorney Docket Number	01017/40451C

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-5,344,915	09-06-1994	LeMaire et al.	
		US-7,253,264	08-07-1997	Lauffer et al.	
		US-5,610,279	03-11-1997	Brockhaus et al.	
		US-5,808,029	09-15-1998	Brockhaus et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	B31	JP-61-293924 - ABSTRACT	12-24-1986	Asahi Chemical Ind.		X

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	D1	Barone et al., Comparative Analysis of the Ability of Etanercept and Infliximab to Lyse TNF-Expressing Cells in a Complement Dependent Fashion. Arthritis Rheum., 42(9) supplement, September 1999 (S90)	
	D2	Bringman et al., Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes. *Hybridoma*, 6(5):489-507 (1987).	
	D3	Byrn et al., Biological properties of a CD4 immunoadhesin. *Nature*, 344:667-70 (1990).	
	D4	Capon et al., Designing CD4 immunoadhesins for AIDS therapy. *Nature*, 337:525-31 (1989).	
	D5	Cosman et al., A new cytokine receptor superfamily. *Trends Biochem. Sci.* 15:265-70 (1990).	
	D6	Deen et al. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. *Nature*, 331(6151): 82-4 (1988).	
	D7	Dembic et al., Two Human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. *Cytokine* 2: 231-237, 1990)	
	D8	Fundamental Immunology, 2nd Edition, Paul, ed., Raven Press, New York, 1989, pp. 679-701	
	D9	BERKE, Functions and mechanisms of lysis induced by cytotoxic T lymphocytes and natural killer cells. Fundamental Immunology, 2nd Edition, Paul, ed., Raven Press, New York, pp. 735-64 (1989).	
	D10	Heller et al., Complementary DNA cloning of a receptor for tumor necrosis factor and	

Examiner Signature		Date Considered	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Manfred Brockhaus
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	2	of	1	Attorney Docket Number	01017/40451C

		demonstration of a shed form of the receptor. *Proc. Natl. Acad. Sci USA,* 87: 6151-5 (1990).	
	D11	Immunology, Type III hypersensitivities induced by immune complexes. Chapter 21, 1st Edition, Klein ed., Blackwell Scientific Publications, Cambridge, MA, pp. 446-447 (1990).	
	D12	Irwin et al, Affinity precipitation methods, Chapter 22, Methods in Molecular Biology, 59: 217-38 (1996).	
	D13	Khare et al, Mechanisms of cell death induced by tumor necrosis factor antagonists. Poster 715 presented at the Annual Meeting of the Society for Investigative Dermatology (SID), May 3-5, 2006, Philadelphia, PA	
	D14	Kohno et al., Adalimumab and Infliximab bind to Fc-receptor and C1q and generate immunoprecipitation: A different mechanism from Etanercept. Presentation 1495, Poster 271, presented at the American College of Rheumatology Annual Meeting, November 13-17, 2005, San Diego, CA	
	D15	Larsson et al., Affinity precipitation of enzymes. *FEBS Lett.* 98(2):333-8 (1979).	
	D16	Mohler et al., Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. *J. Immunol.,* 151:1548-61 (1993).	
	D17	Sell, Immunology, Immunopathology and Immunity, 4th Edition, Elsevier Science Publishing Co., New York, 1987, at pp. 85-91	
	D18	Smith et al., Multimeric structure of the tumor necrosis factor receptor of HeLa cells. *J. Biol. Chem.* 262:6951-4 (1987).	
	D19	Smith et al., A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. *Science,* 248:1019-23 (1990).	
	D20	Traunecker et al., Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. *Nature,* 339:68-70 (1989).	
	D21	Williams et al., Identification of a ligand for the c-kit proto-oncogene. *Cell*, 63: 167-74 (1990).	
	D22	Wingfield et al., Tumour necorsis factor is a compact trimer. *FEBS Lett.* 211: 179-84 (1987).	
	D23	Evans et al., Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. *J. Exp. Med.* 180: 2173-9 (1994).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	